Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

Ozempic maker Novo Nordisk (NVO) shared more details about its experimental anti-obesity pill — that seems to be more ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...